1. Home
  2. PLUS vs URGN Comparison

PLUS vs URGN Comparison

Compare PLUS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

N/A

Current Price

$95.07

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$25.27

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLUS
URGN
Founded
1990
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
PLUS
URGN
Price
$95.07
$25.27
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $60.71
AVG Volume (30 Days)
219.8K
★ 1.2M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 1.14%
N/A
EPS Growth
★ 24.20
N/A
EPS
★ 2.72
N/A
Revenue
★ $2,442,549,000.00
$1,128,000.00
Revenue This Year
$4.67
$190.44
Revenue Next Year
$4.89
$69.25
P/E Ratio
$34.71
★ N/A
Revenue Growth
★ 18.07
N/A
52 Week Low
$73.09
$16.50
52 Week High
$98.21
$50.81

Technical Indicators

Market Signals
Indicator
PLUS
URGN
Relative Strength Index (RSI) 54.64 23.73
Support Level $85.87 $18.28
Resistance Level $98.03 $27.76
Average True Range (ATR) 4.31 2.07
MACD -0.13 -0.72
Stochastic Oscillator 84.64 8.46

Price Performance

Historical Comparison
PLUS
URGN

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: